NEW YORK, Jan. 14, 2016 /PRNewswire/ -- Pomerantz LLP is
investigating claims on behalf of investors of Esperion
Therapeutics, Inc. ("Esperion" or the "Company") (NASDAQ: ESPR).
Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com
or 888-476-6529, ext. 9980.
The investigation concerns whether Esperion and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On August 17, 2015, Esperion
reported to investors that following an August 2015 meeting with the FDA, the FDA had
informed Esperion that the company would not have to complete a
cardiovascular outcomes trial (CVOT) to gain approval of ETC-1002,
Esperion's lead product candidate. Thereafter, on
September 28, 2015, post-market, the
Company announced that the FDA had "encouraged the Company to
initiate a cardiovascular outcomes trial promptly" and that it
might be necessary to complete a CVOT prior to approval.
On this news, Esperion stock fell $16.76, or 47.8%, to close at $18.33 on September 29,
2015.
The Pomerantz Firm, with offices in New York, Chicago, Los
Angeles, and Florida, is
acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late
Abraham L. Pomerantz, known as the
dean of the class action bar, the Pomerantz Firm pioneered the
field of securities class actions. Today, more than 70 years later,
the Pomerantz Firm continues in the tradition he established,
fighting for the rights of the victims of securities fraud,
breaches of fiduciary duty, and corporate misconduct. The Firm has
recovered numerous multimillion-dollar damages awards on behalf of
class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-esperion-therapeutics-inc--espr-300204621.html
SOURCE Pomerantz LLP